Kidney transplantation under FK 506

Kidney transplantation under FK 506.

The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13...

Preliminary Communication Kidney Transplantation Under FK 506

The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13...

Kidney transplantation under FK 506 immunosuppression.

W E RECENTLY reported our initial experience with FK 506 in 36 patients undergoing renal transplan-tation. 1 This series was characterized by a high average complexity. and included 10 patients who also were liver recipients either concomitantly or at an earlier time. Additionally , 2 of the 10 also were given a heart or pancreas. We report here a follow-up of the 26 patients from that original...

Liver, kidney, and thoracic organ transplantation under FK 506.

The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat 120 recipients of primary liver grafts and 20 more patients undergoing liver retransplantation. The patient survival rate after 2 to 8 months in the primary liver transplantation series is 93.3%, with original graft survival of 87.5%. Of the 20 patients in the hepatic retransplant series, 17 (85...

Intestinal transplantation in humans under FK 506.